Scientists uncover a new doorway for SARS-CoV-2 into human cells

Research identifies the human transferrin receptor as an alternative pathway for SARS-CoV-2 infection, offering potential new targets for COVID-19 therapies.

Recent urology trials more likely to include data on harmful effects of treatments

In recent years, clinical trial reports in major urology journals have been more likely to include data on harmful effects of treatments, reports a study

December 22, 2023

Risk Adjusted Net Present Value: What is the current valuation of Santen Pharmaceutical’s Sepetaprost

The revenue for Sepetaprost is expected to reach an annual total of $30 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue

May 16, 2024

Discovery of a novel therapeutic target for pancreatic cancer

A novel amino acid transporter-based therapeutic target for pancreatic ductal adenocarcinoma (PDAC).

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.